Compare AUGO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AUGO | ABVX |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | France |
| Employees | 1462 | 69 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 7.2B |
| IPO Year | N/A | N/A |
| Metric | AUGO | ABVX |
|---|---|---|
| Price | $60.30 | $96.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | $67.60 | ★ $131.31 |
| AVG Volume (30 Days) | 700.8K | ★ 2.2M |
| Earning Date | 05-06-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $91.05 | $52.14 |
| Revenue Next Year | $17.09 | $4,132.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.55 | $5.75 |
| 52 Week High | $110.32 | $148.83 |
| Indicator | AUGO | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 41.67 |
| Support Level | $59.30 | $87.60 |
| Resistance Level | $77.01 | $131.50 |
| Average True Range (ATR) | 4.07 | 7.71 |
| MACD | -0.96 | -1.68 |
| Stochastic Oscillator | 29.98 | 41.16 |
Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments include: Minosa Mine, Apoena Mine, the Aranzazu Mine, Almas Mine, Borborema Mine and Serra Grande Mine. It derives maximum revenue from Aranzazu Mine. The company's growth projects include: Matupa in Brazil, and Era Dorada in Guatemala. whereas its exploration projects include: Carajas, in Brazil, and Tolda Fria in Colombia.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.